Cargando…
No association between APOE genotype and lipid lowering with cognitive function in a randomized controlled trial of evolocumab
APOE encodes a cholesterol transporter, and the ε4 allele is associated with higher circulating cholesterol levels, ß-amyloid burden, and risk of Alzheimer’s disease. Prior studies demonstrated no significant differences in objective or subjective cognitive function for patients receiving the PCSK9...
Autores principales: | Korthauer, Laura E., Giugliano, Robert P., Guo, Jianping, Sabatine, Marc S., Sever, Peter, Keech, Anthony, Atar, Dan, Kurtz, Christopher, Ruff, Christian T., Mach, Francois, Ott, Brian R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9000128/ https://www.ncbi.nlm.nih.gov/pubmed/35404972 http://dx.doi.org/10.1371/journal.pone.0266615 |
Ejemplares similares
-
Sudden Fall in the Lipid-Lowering Effect of Evolocumab: The Butler Is Not Always Guilty
por: Fogacci, Federica, et al.
Publicado: (2021) -
Sudden Fall in the Lipid-Lowering Effect of Evolocumab: The Butler Is Not Always Guilty
por: Fogacci, Federica, et al.
Publicado: (2021) -
Effect of plasma lipids and APOE genotype on cognitive decline
por: Yasuno, Fumihiko, et al.
Publicado: (2013) -
Effects of Evolocumab on the ApoA1 Remnant Ratio: A Pooled Analysis of Phase 3 Studies
por: May, Heidi T., et al.
Publicado: (2019) -
Effectiveness, Adherence, and Safety of Evolocumab in a Swiss Multicenter Prospective Observational Study
por: Nanchen, David, et al.
Publicado: (2021)